Close Menu

legal settlement

The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.

The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad. 

By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.

The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for  patients who had not been in remission for five years and who had not been taking tamoxifen.

The company agreed to settle a lawsuit alleging it improperly billed government health plans for its genetic tests.

The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.

The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order. 

The Wall Street Journal reports that the erstwhile partners have reached a settlement of more than $25 million.

In a recent regulatory filing, Thermo disclosed that it acquired Core Informatics for $94 million and Finesse Solutions for $220 million.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.